HHS and DOD announced $12.7 million contract with InBios to boost US production of rapid COVID-19 tests

, , , ,

On Oct. 30, 2020, the U.S. Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), awarded a contract action with a not-to-exceed value of $12.67 million to InBios International.  This effort will expand US based industrial production capacity of two point of care, rapid COVID-19 tests: SCoV-2 Ag Detect™ Kit, an antigen COVID-19 test, and SCoV-2 Detect™ IgM/IgG Kit, a serological COVID-19 response test.

This industrial base expansion effort will allow InBios to increase their production capacity to 400,000 units per week by May 2021, a capacity increase of 20 times their current output.

The DOD’s Defense Assisted Acquisition (DA2) Cell led this effort in coordination with the Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT).  The Biomedical Advanced Research and Developmental Authority (BARDA) within the HHS funded this award through the Health Care Enactment Act (HCEA) in support of domestic industrial base expansion for critical medical resources.

Tags:


Source: U.S. Department of Defense
Credit:

LifeScienceHistory.com offers three advertising package options. Each package lnclude at least two digital images for multiple page placements and maximum exposure! Rates range from just $300 to $500 per month.